Previous 10 | Next 10 |
SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The res...
FDA laboratory testing confirms SAB-185 neutralizes Omicron and other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad neutralization to viral variants SAB-185 ...
SAB Biotherapeutics is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. The Company's Tc Bovine-based DiversitAb platform has presented two PoCs in the past two months. The Company’s developmen...
SAB Biotherapeutics Inc. (NASDAQ:SABS) traded today at a new 52-week high of $12.03. This new high was reached on approximately average trading volume as 393,000 shares traded hands, while the average 30-day volume is approximately 502,000 shares. SAB Biotherapeutics Inc. (NASDAQ:SABS) i...
SAB Biotherapeutics (NASDAQ:SABS) announced that its Phase 2a challenge study for experimental seasonal influenza therapy SAB-176 met the primary endpoint with statistical significance. However, the shares have lost ~2.5% in the pre-market. In the placebo-controlled study initiated ...
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical results con...
Gainers: iSpecimen (NASDAQ:ISPC) +115%. Biofrontera (NASDAQ:BFRI) +68%. Allied Healthcare Products (NASDAQ:AHPI) +56%. NRx Pharmaceuticals (NASDAQ:NRXP) +52%. Adagio (NASDAQ:ADGI) +31%. Alpha Pro Tech (NYSE:APT) +23%. 180 Life Sciences (NASDAQ:ATNF) +20%. Moderna (NASDAQ:MRNA) +22%. SAB Bioth...
SAB Biotherapeutics (NASDAQ:SABS): 9M Net Loss $5.6M Cash and cash equivalents on September 30, 2021 were $10.8M as compared to $13.5M as of September 30, 2020. Press Release For further details see: SAB Biotherapeutics reports 9M results
Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded scope for advancement of SAB-185 Strengthened leadership team through app...
SAB Biotherapeutics Inc. (NASDAQ:SABS) traded at a new 52-week high today of $11.75. This new high was reached on approximately average trading volume as 393,000 shares traded hands, while the average 30-day volume is approximately 415,000 shares. There is potential upside of 15.3% for s...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Website:
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...